{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:37Z","timestamp":1792025197801,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"DOI":"10.1007\/s12072-026-11164-7","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:08Z","timestamp":1792022828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world multicenter study of statins in compensated advanced chronic liver disease on hepatic decompensation and mortality outcomes"],"prefix":"10.1007","author":[{"given":"Cheng Han","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Apoorva","family":"Sasikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-9214","authenticated-orcid":false,"given":"Margaret L. P.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy Che-To","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karn","family":"Wijarnpreecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichat","family":"Kaewdech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand V.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitchai","family":"Rattananukrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shadab","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Tsochatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the CORE Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira G.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd B.","family":"Aboona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Rangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakktivel","family":"Elangovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajit","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimsiri","family":"Sripongpun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naichaya","family":"Chamroonkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathwika","family":"Pasham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingkai","family":"Tioh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"3","key":"11164_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70001","volume":"45","author":"EKJ Tham","year":"2021","unstructured":"Tham EKJ, Tan DJH, Danpanichkul P, et al. The global burden of cirrhosis and other chronic liver diseases in 2021. Liver Int. 2021;45(3): e70001","journal-title":"Liver Int"},{"issue":"27","key":"11164_CR2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i27.6201","volume":"22","author":"M Janicko","year":"2016","unstructured":"Janicko M, Drazilova S, Pella D, Fedacko J, Jarcuska P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016;22(27): 6201","journal-title":"World J Gastroenterol"},{"issue":"1","key":"11164_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bcp.12182","volume":"77","author":"A Albarmawi","year":"2014","unstructured":"Albarmawi A, Czock D, Gauss A, et al. CYP3A activity in severe liver cirrhosis correlates with Child\u2013Pugh and model for end\u2010stage liver disease (MELD) scores. Br J Clin Pharmacol. 2014;77(1):160\u2013169","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"11164_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gutjnl-2019-318237","volume":"69","author":"J Bosch","year":"2020","unstructured":"Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut. 2020;69(5):953\u2013962","journal-title":"Gut"},{"issue":"2","key":"11164_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/CLD.0000000000000015","volume":"22","author":"J Gratac\u00f3s-Gin\u00e8s","year":"2023","unstructured":"Gratac\u00f3s-Gin\u00e8s J, Pose E. Review of the role of statins in cirrhosis and portal hypertension. Clin Liver Dis. 2023;22(2):50\u201357","journal-title":"Clin Liver Dis"},{"issue":"10","key":"11164_CR6","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/ajg.2017.170","volume":"112","author":"S Kamal","year":"2017","unstructured":"Kamal S, Khan MA, Seth A, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(10):1495\u20131505","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"11164_CR7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/ajg.2016.179","volume":"111","author":"Y-W Huang","year":"2016","unstructured":"Huang Y-W, Lee C-L, Yang S-S, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am J Gastroenterol. 2016;111(7):976\u2013985","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"11164_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/hep.29172","volume":"66","author":"FM Chang","year":"2017","unstructured":"Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus\u2013and hepatitis C virus\u2013related cirrhosis: a population\u2010based study. Hepatology. 2017;66(3):896\u2013907","journal-title":"Hepatology"},{"issue":"7","key":"11164_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/apt.14243","volume":"46","author":"UC Bang","year":"2017","unstructured":"Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case\u2010cohort study. Aliment Pharmacol Ther. 2017;46(7):673\u2013680","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"11164_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s44355-025-00020-4","volume":"2","author":"J Ruan","year":"2025","unstructured":"Ruan J, Fang Y, Zhang X, Zhang Q, Song J. Statins exposure and adverse events in participants with chronic viral hepatitis: a meta-analysis based on cohort studies. npj Gut Liver. 2025;2(1): 7","journal-title":"npj Gut Liver"},{"issue":"5","key":"11164_CR11","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","volume":"150","author":"JG Abraldes","year":"2016","unstructured":"Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160-1170. e1163","journal-title":"Gastroenterology"},{"key":"11164_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70526","author":"BdF Moraes","year":"2026","unstructured":"Moraes BdF, Leite GAPD, Silveira IB, et al. Statin therapy independently reduces mortality and liver complications in patients with cirrhosis: an updated systematic review and meta\u2010analysis. Aliment Pharmacol Ther. 2026. https:\/\/doi.org\/10.1111\/apt.70526","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"11164_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521-1530. e1528","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"11164_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E Von Elm","year":"2014","unstructured":"Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495\u20131499","journal-title":"Int J Surg"},{"issue":"20","key":"11164_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"WM Association","year":"2013","unstructured":"Association WM. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20132194","journal-title":"JAMA"},{"issue":"4","key":"11164_CR16","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R De Franchis","year":"2022","unstructured":"De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII\u2013renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u2013974","journal-title":"J Hepatol"},{"issue":"2","key":"11164_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/hep.24418","volume":"54","author":"A Berzigotti","year":"2011","unstructured":"Berzigotti A, Garcia\u2010Tsao G, Bosch J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54(2):555\u2013561","journal-title":"Hepatology"},{"issue":"4","key":"11164_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jamacardio.2018.0022","volume":"3","author":"SS Khan","year":"2018","unstructured":"Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):48\u201355","journal-title":"JAMA Cardiol"},{"issue":"9","key":"11164_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","volume":"8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Noureddin N, Ajmera V, et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(9):829\u2013836","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"11164_CR20","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/cid\/cit603","volume":"57","author":"Y-W Huang","year":"2013","unstructured":"Huang Y-W, Wang T-C, Lin S-C, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis. 2013;57(12):1695\u20131702","journal-title":"Clin Infect Dis"},{"issue":"1","key":"11164_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45(1):89\u2013118","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"11164_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","volume":"150","author":"A Mohanty","year":"2016","unstructured":"Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C\u2013related compensated cirrhosis. Gastroenterology. 2016;150(2):430-440. e431","journal-title":"Gastroenterology"},{"issue":"6","key":"11164_CR23","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jceh.2023.05.002","volume":"13","author":"LR Shaffer","year":"2023","unstructured":"Shaffer LR, Mahmud N. Statins in cirrhosis: hope or hype? J Clin Exp Hepatol. 2023;13(6):1032\u20131046","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"11164_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"C Zafra","year":"2004","unstructured":"Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749\u2013755","journal-title":"Gastroenterology"},{"issue":"4","key":"11164_CR25","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","volume":"53","author":"J Trebicka","year":"2010","unstructured":"Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010;53(4):702\u2013712","journal-title":"J Hepatol"},{"issue":"1","key":"11164_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","volume":"70","author":"E Pose","year":"2019","unstructured":"Pose E, Trebicka J, Mookerjee RP, Angeli P, Gin\u00e8s P. Statins: old drugs as new therapy for liver diseases? J Hepatol. 2019;70(1):194\u2013202","journal-title":"J Hepatol"},{"key":"11164_CR27","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","volume":"75","author":"C Engelmann","year":"2021","unstructured":"Engelmann C, Cl\u00e0ria J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 2021;75:S49\u2013S66","journal-title":"J Hepatol"},{"issue":"10","key":"11164_CR28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2024.27441","volume":"333","author":"E Pose","year":"2025","unstructured":"Pose E, Jim\u00e9nez C, Zaccherini G, et al. Simvastatin and rifaximin in decompensated cirrhosis: a randomized clinical trial. JAMA. 2025;333(10):864\u2013874","journal-title":"JAMA"},{"issue":"5","key":"11164_CR29","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"JG Abraldes","year":"2009","unstructured":"Abraldes JG, Albillos A, Ba\u00f1ares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651\u20131658","journal-title":"Gastroenterology"},{"key":"11164_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2026.05.010","author":"F Cattazzo","year":"2026","unstructured":"Cattazzo F, Cinque F, Di Maria V, et al. Statins in chronic liver disease and its complications: an umbrella review and meta-analysis of systematic reviews. Dig Liver Dis. 2026. https:\/\/doi.org\/10.1016\/j.dld.2026.05.010","journal-title":"Dig Liver Dis"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11164-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:07:09Z","timestamp":1792022829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11164-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":30,"alternative-id":["11164"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11164-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H.N serves as the CEO of LiverGENIX Pte Ltd. VLC received research grants from AstraZeneca, KOWA, and Ipsen, paid to University of Michigan. Apichat Kaewdech received research grants or support from Roche, Roche Diagnostics, and Abbott Laboratories, and honoraria from Roche, Roche Diagnostics, Abbott Laboratories, and Esai. M.-H.Z. has received honoraria for lectures from AstraZeneca, Hisky Medical Technologies, and Novo Nordisk and consulting fees from Boehringer Ingelheim and serves as a consultant for Eieling Technology. MN consults and received grants from Gilead, GlaxoSmithKline, Madrigal, Novo Nordisk, Takeda, and Terns. He consults, advises, and owns stock in Cytodyn. He consults and advises 89BIO, Altimmune, Boehringer Ingelheim, Merck, and Perspecturm. He has received grants and owns stock in Viking. He advises Blade, cohBar, EchoSens, Fractyl, Intercept, NorthSea, Pfizer, Siemens, and Roche Diagnostics. He has received grants from Allergan, Bristol Myers Squibb, Conatus, Corcept, Enanta, Galmed, Galectin, Genfit, Madrigal, Novartis, Pfizer, Shire, and Zydus. He owns stock in Anaetos, ChronWell, Cima, and Rivus Pharma. Rebeca Mayo is employed by OWL Metabolomics. M.D.M has served as a consultant to Roche, Estella and Gilead. He has been an advisor for LernaBio. M.M has received payment from speaking at Boston Scientific, Olympus Medical, Roche, and Astellas. He also serves as the CMO of LiverGENIX PTE LTD. M.D.M is supported by the Singapore Ministry of Health through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd under the NMRC Clinician Scientist-Individual Research Grant (MOH-001228) and NMRC Clinician Scientist Award (MOH-001631), as well as the National Research Foundation, Singapore (NRF) under the NMRC Open Fund\u2014Large Collaborative Grant (MOH-001325) and administered by the Singapore Ministry of Health through the NMRC Office, MOH Holdings Pte Ltd.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ChatGPT was used to refine the writing of the first draft of the manuscript, which was subsequently reviewed and approved by all authors.","order":2,"name":"Ethics","label":"Declaration","group":{"name":"EthicsHeading","label":"Declarations"}}]}}